Optimi Health Provides Corporate Update
Optimi Health (OTCQX: OPTHF), a GMP-certified MDMA and psilocybin manufacturer, has announced two significant updates. First, the company has engaged MZ Investor Relations for strategic capital markets support at US$9,000-13,500 monthly, granting them 1.9 million stock options with varying exercise prices and vesting schedules.
On the manufacturing front, Optimi has achieved a milestone by completing production of over 3,000 GMP doses of 5mg natural psilocybin extract capsules. These will be used to treat Treatment-Resistant Depression patients in Australia and supply upcoming Phase 2 clinical trials globally. The company offers GMP-certified MDMA capsules (40mg and 60mg), psilocybin capsules, and APIs to licensed distributors and pharmaceutical companies.
Optimi Health (OTCQX: OPTHF), produttore certificato GMP di MDMA e psilocibina, ha annunciato due aggiornamenti rilevanti. Innanzitutto, la società ha ingaggiato MZ Investor Relations per supporto strategico nei mercati dei capitali a un costo mensile di US$9.000-13.500, concedendo loro 1,9 milioni di opzioni su azioni con prezzi di esercizio e piani di maturazione differenziati.
Sul fronte produttivo, Optimi ha raggiunto un traguardo completando la produzione di oltre 3.000 dosi GMP di capsule contenenti 5 mg di estratto naturale di psilocibina. Queste dosi saranno impiegate per trattare pazienti con Depressione Resistenti al Trattamento in Australia e per rifornire i prossimi trial clinici di Fase 2 a livello globale. L'azienda fornisce capsule GMP di MDMA (40 mg e 60 mg), capsule di psilocibina e principi attivi (API) a distributori autorizzati e società farmaceutiche.
Optimi Health (OTCQX: OPTHF), fabricante certificado GMP de MDMA y psilocibina, ha comunicado dos novedades importantes. En primer lugar, la compañía ha contratado a MZ Investor Relations para apoyo estratégico en los mercados de capital a un coste mensual de US$9,000-13,500, otorgándoles 1,9 millones de opciones sobre acciones con distintos precios de ejercicio y calendarios de adquisición.
En el ámbito de la fabricación, Optimi ha alcanzado un hito al completar la producción de más de 3,000 dosis GMP de cápsulas de 5 mg de extracto natural de psilocibina. Estas dosis se usarán para tratar a pacientes con Depresión Resistente al Tratamiento en Australia y para abastecer los próximos ensayos clínicos de Fase 2 a nivel mundial. La empresa ofrece cápsulas GMP de MDMA (40 mg y 60 mg), cápsulas de psilocibina y APIs a distribuidores autorizados y compañías farmacéuticas.
Optimi Health (OTCQX: OPTHF), GMP 인증을 받은 MDMA 및 실로시빈 제조업체가 두 가지 주요 소식을 발표했습니다. 우선 회사는 자본시장 전략 지원을 위해 MZ Investor Relations와 계약을 체결했으며 월 US$9,000-13,500의 비용으로 190만 주의 스톡옵션을 부여했습니다. 이 스톡옵션은 행사 가격과 베스팅 일정이 다르게 설정되어 있습니다.
제조 측면에서는 Optimi가 5mg 천연 실로시빈 추출물 캡슐 3,000회분 이상(GMP 기준) 생산을 완료하는 성과를 거뒀습니다. 이 물량은 호주에서 치료저항성 우울증 환자 치료에 사용되고 전 세계에서 예정된 2상 임상시험에 공급될 예정입니다. 회사는 GMP 인증 MDMA 캡슐(40mg 및 60mg), 실로시빈 캡슐 및 원료 의약품(API)을 허가받은 유통업체와 제약사에 제공합니다.
Optimi Health (OTCQX: OPTHF), fabricant certifié GMP de MDMA et de psilocybine, a annoncé deux informations importantes. Premièrement, la société a mandaté MZ Investor Relations pour un soutien stratégique sur les marchés de capitaux, moyennant 9 000 à 13 500 USD par mois, et lui a accordé 1,9 million d’options sur actions avec des prix d’exercice et des calendriers d’acquisition variables.
Sur le plan de la fabrication, Optimi a franchi une étape en complétant la production de plus de 3 000 doses GMP de gélules de 5 mg d’extrait naturel de psilocybine. Ces doses serviront à traiter des patients souffrant de dépression résistante au traitement en Australie et à approvisionner les prochains essais cliniques de phase 2 dans le monde. L’entreprise fournit des gélules MDMA certifiées GMP (40 mg et 60 mg), des gélules de psilocybine et des API à des distributeurs agréés et des sociétés pharmaceutiques.
Optimi Health (OTCQX: OPTHF), ein GMP-zertifizierter Hersteller von MDMA und Psilocybin, hat zwei bedeutende Neuigkeiten bekanntgegeben. Zum einen hat das Unternehmen MZ Investor Relations für strategische Kapitalmarktunterstützung engagiert und zahlt dafür monatlich US$9.000-13.500. Zudem wurden 1,9 Millionen Aktienoptionen mit unterschiedlichen Ausübungspreisen und Vesting-Plänen gewährt.
Auf der Produktionsseite hat Optimi einen Meilenstein erreicht und die Herstellung von über 3.000 GMP-Dosen von 5 mg Kapseln mit natürlichem Psilocybin-Extrakt abgeschlossen. Diese Dosen sollen zur Behandlung von Patienten mit therapieresistenter Depression in Australien eingesetzt und für bevorstehende Phase-2-Studien weltweit bereitgestellt werden. Das Unternehmen liefert GMP-zertifizierte MDMA-Kapseln (40 mg und 60 mg), Psilocybin-Kapseln und Wirkstoffe (APIs) an lizenzierte Distributoren und Pharmafirmen.
- Successfully manufactured over 3,000 GMP doses of psilocybin capsules for clinical use
- Expanded market reach through engagement with MZ Investor Relations for strategic capital markets support
- Products available for Treatment-Resistant Depression treatment in Australia under Authorized Prescribers Scheme
- Significant equity dilution through 1.9 million stock options granted to IR firm
- Monthly IR expenses of up to US$13,500 represent additional operational costs
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a manufacturer of GMP-certified MDMA and psilocybin, is pleased to announce it has entered into an agreement with MZ Investor Relations ("MZ"), an investor relations firm. MZ will provide Optimi with strategic support in capital markets advisory, corporate communications, and investor engagement.
Under the terms of the engagement, MZ will be paid US
For more information on MZ, please visit: www.mzgroup.us.
Manufacturing Update
Optimi is also pleased to report a production milestone with the completion of manufacturing and encapsulation of over 3,000 GMP doses of its 5mg natural psilocybin extract capsules. A portion of this batch will be used to treat patients with Treatment-Resistant Depression (TRD) in Australia under its Authorized Prescribers Scheme, and to supply upcoming Phase 2 clinical trials in both Canada and abroad.
Ordering From Optimi
Licensed U.S. distributors and pharmaceutical companies holding the appropriate permits and DEA registrations may order Optimi's GMP-certified 40mg and 60mg MDMA capsules, 5mg natural psilocybin extract capsules, and API of both substances directly.
Authorized organizations in other jurisdictions with the required approvals and regulatory clearances may also access Optimi products for use in clinical trials, research, or compliant commercial distribution frameworks.
In Australia, entities seeking access to Optimi's MDMA and psilocybin products under the Authorized Prescribers Scheme may do so through Mind Medicine Australia.
To initiate procurement, contact:
sales@optimihealth.ca
About Optimi Health Corp.
Optimi Health Corp. is a Health Canada-licensed, GMP-compliant manufacturer and supplier of natural psilocybin and MDMA. Dedicated to producing high-quality psychedelic products, the Company aims to support the global advancement of mental health therapies through rigorous compliance, innovation, and collaboration.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10615/263172_42190ce5a465ba66_001full.jpg
On Behalf of the Board
JJ Wilson, Chair of the Board
For more information, please contact:
Optimi Health Corp.
Telephone: (778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca
Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements"). Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed in the Company's long form prospectus dated February 12, 2021, a copy of which is available on SEDAR+ at www.sedarplus.com. Except as expressly required by applicable law, Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263172
FAQ
What is the new manufacturing milestone announced by Optimi Health (OPTHF)?
What are the terms of Optimi Health's agreement with MZ Investor Relations?
What products does Optimi Health (OPTHF) currently manufacture?
How can organizations access Optimi Health's psilocybin and MDMA products?
